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Abstract: Expression of the nucleolar chaperones nucleolin (NCL) and nucleophosmin (NPM1), upstream binding 
transcription factor (UBTF), rRNA18S, rRNA28S, and several genes encoding ribosomal proteins (RPs) is decreased 
in frontal cortex area 8 at advanced stages of Alzheimer’s disease (AD). This is accompanied by reduced protein 
levels of elongation factors eEF1A and eEF2. Changes are more marked in AD cases with rapid course (rpAD), as 
initiation factor eIF3η is significantly down-regulated and several RP genes up-regulated in rpAD when compared 
with typical AD. These changes contrast with those seen in APP/PS1 transgenic mice used as a model of AD-like 
β-amyloidopathy; Ncl mRNA, rRNA18S, rRNA28S and seven out of fifteen assessed RP genes are up-regulated in 
APP/PS1 mice aged 20 months; only eEF2 protein levels are reduced in transgenic mice. Our findings show marked 
altered expression of molecules linked to the protein synthesis machinery from the nucleolus to the ribosome in 
frontal cortex at terminal stages of AD which differs from that seen in APP/PS1 transgenic mice, thus further sug-
gesting that molecular signals in mouse models do not apply to real human disease counterparts.
Keywords: Alzheimer’s disease, protein synthesis, nucleolar chaperones, rRNAs, transcription, translation, APP/
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Introduction
Brain atrophy in Alzheimer’s disease (AD) and 
other neurodegenerative diseases is commonly 
considered the result of a combination of fac-
tors including nerve cell atrophy, nerve cell loss 
and reduced myelin fibers in the white matter. 
Since nerve cell loss is produced as a conse-
quence of neuron death whatever the mecha-
nism involved, neuron atrophy implies increased 
catabolism, reduced protein and other biomol-
ecule/substrate synthesis, or a mixed scenario. 
In certain settings, reduced protein synthesis 
may lead to neuronal atrophy but also to cell 
death. Despite the importance of altered pro-
tein synthesis in AD, most data come from indi-
vidual observations which focus on the nucleo-
lus and the ribosome. The surface of nuclear 
organizer region (NOR)/total nucleus surface is 
reduced [1, 2], the rRNA gene promoter is hyper-
methylated, suggesting epigenetic rRNA silenc-
ing [3], rRNA levels are reduced, there is 
increased RNA oxidation [4-10], the expression 
of certain transcription factors is reduced [11-
13], and incorporation of S35 methionine into 
AD brain ribosomes is decreased [9, 14].
Here we report a detailed study of the dentate 
gyrus and hippocampus at different stages of 
AD showing altered mRNA and protein expres-
sion of nucleolar chaperones nucleolin (NCL), 
nucleophosmin (NPM1) and nucleoplasmin 3 
(NPM3), and upstream binding transcription 
factor RNA polymerase I (UBTF); altered 28S- 
RNA; decreased expression of genes encoding 
ribosomal proteins; and altered protein expres-
sion of several initiation and elongation transla-
tion factors [15]. Since these alterations are 
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region-dependent (they differ in CA1 and den-
tate gyrus), we decided to analyze frontal cor-
tex area 8 at terminal stages of AD using the 
same probes and methods. We also compared 
AD cases with the typical clinical course of 
cases with rapid clinical course (rpAD) [16] to 
learn whether differences in disease progres-
sion are associated with particular changes in 
the protein synthesis machinery. Finally, we 
compared changes in AD with those seen in the 
somatosensory cortex of APP/PS1 transgenic 
mice used as a model of AD-like β-amyloidopathy.
Material and methods
Subjects
Brain tissue was obtained from the Institute of 
Neuropathology HUB-ICO-IDIBELL Biobank and 
the Hospital Clinic-IDIBAPS Biobank following 
the guidelines of Spanish legislation on this 
matter and the approval of the local ethics 
committee. Processing of brain tissue has 
been detailed elsewhere [17]. The post-mortem 
interval between death and tissue processing 
was from 3 to 18 hours. One hemisphere was 
immediately cut in coronal sections, 1 cm thick, 
and selected areas of the encephalon were rap-
idly dissected, frozen on metal plates over dry 
ice, placed in individual air-tight plastic bags 
and stored at -80°C until use for biochemical 
studies. The other hemisphere was fixed by 
immersion in 4% buffered formalin for 3 weeks 
for morphological studies. Neuropathological 
diagnosis in all cases was based on the routine 
study of 20 selected de-waxed paraffin sec-
tions comprising different regions of the cere-
bral cortex, diencephalon, thalamus, brain 
stem and cerebellum, which were stained with 
haematoxylin and eosin, and Klüver-Barrera, 
and for immunohistochemistry for microglia, 
glial fibrillary acidic protein, β-amyloid, phos-
phorylated tau (clone AT8), α-synuclein, TDP-
43, ubiquitin and p62. Stages of neurofibrillary 
tangle pathology [18, 19], phases of AD-related 
β-amyloid plaques [20] and ABC score were 
assigned according to current consensus 
guidelines [21]. All AD cases were sporadic. 
Neuropathological data were assessed by two 
independent observers. AD cases were 5 men 
and 3 women, mean age 85 ± 5.7 years; rpAD 
cases were 4 men and 4 women, mean age 
79.2 ± 5.1 years. AD and rpAD cases had simi-
lar degrees of AD-related pathology. We used 
as controls middle-aged cases (MA, n = 12: 7 
men, 5 women; mean age 59.9 ± 15.5 years) 
who had not suffered from neurologic, psychi-
atric, or metabolic diseases (including meta-
bolic syndrome), and did not have abnormali-
ties in the neuropathological examination 
excepting Braak stage I-II of NFT pathology with 
no β-amyloid deposition. A summary of human 
cases is shown in Table 1.  
APP/PS1 mice 
APP/PS1 mice and wild-type (WT) littermates 
aged 3, 12 and 20 months (n = 7 for each phe-
notype and time-period; total number of ani-
Table 1. Summary of human cases used in the 
present study 
Case Diagnosis Gender Age PM delay RIN WB
1 MA M 64 8 h 30 7.7 X
2 MA M 56 5 h 7.1 X
3 MA M 67 5 h 7 X
4 MA M 62 3 h 7.2 X
5 MA M 52 4 h 40 m 7.9 X
6 MA M 30 4 h 10 m 8.4 X
7 MA M 53 3 h 7.7 X
8 MA F 49 7 h 8.2 X
9 MA F 75 3 h 6.5 X
10 MA F 46 9 h 35 m 7.2 X
11 MA F 86 4 h 15 m 8.4 X
12 MA F 79 3 h 35 m 8 X
13 AD F 89 8 h 50 m 6.5 X
14 AD M 81 7 h 30 m 6.1 X
15 AD M 91 7 h 7.3 X
16 AD F 86 9 h 7.3 X
17 AD M 92 7 h 45 m 6.5 X
18 AD F 84 7 h 45 m 7.1 X
19 AD M 82 5 h 7.1 X
20 AD M 75 8 h 15 m 6.5 X
21 rpAD M 69 18 h 7.2 X
22 rpAD F 85 6 h 6.4 X
23 rpAD F 76 18 h 6 X
24 rpAD F 79 5 h 30 m 6.9 X
25 rpAD M 83 5 h 30 m 6.4 X
26 rpAD M 83 8 h 20 m 6.6 X
27 rpAD F 81 6 h 6.8 X
28 rpAD M 78 3 h 30 m 7 X
MA: middle-aged individuals with no neurological symp-
toms and no brain lesions on neuropathological study. AD: 
Alzheimer’s disease cases with typical prolonged advanced 
dementia, Braak stage V-VI of neurofibrillary tangle pathol-
ogy, Thal phase of β-amyloid and CERAD score C; rpAD: 
cases with clinical and neuropathological characteristics 
similar to AD but with a rapid course equal to or less than 
2 years. M: male; F: female; PM delay: post-mortem delay; 
RIN: RNA integrity number (cases assessed with RT-qPCR); 
WB: cases used for western blotting.
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mals = 42) were used. Mice expressing human 
mutated forms APPswe and PS1dE9 [22] show 
the first β-amyloid deposits at the age of 3 
months and altered memory and learning 
capacities by the age of six months [23]. 
Animals were maintained under standard ani-
mal housing conditions in a 12-hour dark-light 
cycle with free access to food and water. 
Transgenic mice were characterized by geno-
typing from genomic DNA isolated from tail 
clips using the polymerase chain reaction (PCR) 
conditions proposed. Animals were kept under 
the same conditions as stated above. All ani-
mal procedures were conducted according to 
ethical guidelines (European Communities Co- 
uncil Directive 86/609/EEC) and were approv- 
ed by the local ethics committee.  
RNA purification
Purification of RNA from right frontal cortex 
area 8 in human cases and somatosensory cor-
tex in mice aged 3, 12 and 20 months (n = 7 
per age and phenotype) was carried out using 
RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, 
Germany) following the protocol provided by 
the manufacturer, and performing the optional 
DNase digest to avoid extraction and subse-
quent amplification of genomic DNA. The con-
centration of each sample was obtained from 
A260 measurements with a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Walth- 
am, MA, USA). RNA integrity was tested using 
the Agilent 2100 BioAnalyzer (Agilent, Santa 
Clara, CA, USA). Values for RNA integrity num-
ber (RIN) varied from 6.1 to 8.4 in human cases 
(Table 1). Post-mortem delay had no effect on 
RIN values in the present series (Table 1). RIN 
values in mice were greater than 8.
Retrotranscription reaction
Retrotranscription reaction of RNA samples 
selected based on their RIN values was carried 
Table 2A. Probes used for RT-qPCR analysis in human cases
Gene Full name Reference 
Housekeeping genes
    GUS-B β-glucuronidase Hs00939627_m1
    XPNPEP1 X-prolylaminopeptidase (aminopeptidase P) 1 Hs00958026_m1
    AARS Alanyl-tRNA synthetase Hs00609836_m1
    HPRT Hypoxanthine phosphoribosyltransferase 1 Hs_02800695_m1
Nucleolar, rRNAs and genes encoding ribosomal protein
    NCL Nucleolin Hs01066668_m1
    NPM1 Nucleophosmin (nucleolar phospho-protein B23, numatrin) Hs02339479_m1
    rRNA 28S RNA, 28S ribosomal 5 Hs03654441_s1
    rRNA 18S Eukaryotic 18S rRNA Hs99999901_s1
    UBTF Upstream binding transcription factor, RNA polymerase I Hs01115792_g1
    RPL5 Ribosomal protein L5 Hs_03044958_g1
    RPL7 Ribosomal protein L7 Hs_02596927_g1
    RPL21 Ribosomal protein L21 Hs_00823333_s1
    RPL22 Ribosomal protein L22 Hs_01865331_s1
    RPL23A Ribosomal protein L23A Hs_01921329_g1
    RPL26 Ribosomal protein L26 Hs_00864008_m1
    RPL27 Ribosomal protein L27 Hs_03044961_g1
    RPL30 Ribosomal protein L30 Hs_00265497_m1
    RPL31 Ribosomal protein L31 Hs_0101549_g1
    RPS3A Ribosomal protein S3A Hs_00832893_sH
    RPS5 Ribosomal protein S5 Hs_00734849_g1
    RPS6 Ribosomal protein S6 Hs_04195024_g1
    RPS10 Ribosomal protein S10 Hs_01652370_gH
    RPS13 Ribosomal protein S13 Hs_01011487_g1
    RPS16 Ribosomal protein S16 Hs_01598516_g1
    RPS17 Ribosomal protein S17 Hs_00734303_g1
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out with the High-Capacity cDNA Archive kit 
(Applied Biosystems, Foster City, California, 
USA) following the guidelines provided by the 
manufacturer, and using Gene Amp® 9700 PCR 
System thermocycler (Applied Biosystems). A 
parallel reaction for one RNA sample was pro-
cessed in the absence of reverse transcriptase 
to rule out DNA contamination.
Real time PCR
Real Time quantitative PCR (RT-qPCR) assays 
were conducted in duplicate on 1,000 ng of 
cDNA samples obtained from the retrotrans-
cription reaction, diluted 1:20 in 384-well opti-
cal plates (Kisker Biotech, Steinfurt, GE) utiliz-
ing the ABI Prism 7900 HT Sequence Detection 
System (Applied Biosystems). Parallel amplifi-
cation reactions were carried out using 20× 
TaqMan Gene Expression Assays and 2× 
TaqMan Universal PCR Master Mix (Applied Bio- 
systems). Human and mouse TaqMan probes 
are shown in Table 2A and 2B, respectively.
Parallel assays for each sample were carried 
out using probes for β-glucuronidase (GUS-β), 
X-prolyl aminopeptidase (aminopeptidase P) 
1 (XPNPEP1), alanyl-transfer RNA synthase 
(AARS) and hypoxanthine-guanine phosphori-
bosyltranferase (HPRT) for normalization. Hou- 
sekeeping genes were selected because they 
show no modifications in several neurodegen-
erative diseases in human post-mortem brain 
tissue [24, 25]. The reactions were performed 
using the following parameters: 50°C for 2 min, 
95°C for 10 min, 40 cycles at 95°C for 15 s and 
60°C for 1 min. TaqMan PCR data were cap-
tured using the Sequence Detection Software 
(SDS version 2.2, Applied Biosystems). Subse- 
quently, threshold cycle (CT) data for each sam-
ple were analyzed with the double delta CT 
(ΔΔCT) method. First, delta CT (ΔCT) values 
Table 2B. Probes used for RT-qPCR analysis in mice
Gene Full name Reference 
Housekeeping genes
    Gus-B β-glucuronidase Mm01197698_m1
    Xpnpep11 X-prolylaminopeptidase (aminopeptidase P) 1 Mm00460040_m1
    Aars Alanyl-tRNA synthetase Mm00507627_m1
    Hprt Hypoxanthine phosphoribosyltransferase 1 Mm01545399_m1
Nucleolar, rRNAs and genes encoding ribosomal protein
    Ncl Nucleolin Mm01290591_m1
    Npm3 Nucleophosmin/nucleoplasmin 3 Mm00784254_s1 
    rRNA 28S RNA, 28S ribosomal 5 Mm03682676_s1
    rRNA 18S Eukaryotic 18S rRNA Mm03928990_g1
    Ubtf Upstream binding transcription factor, RNA polymerase I Mm00456972_m1
    Rpl5 Ribosomal protein L5 Mm00847026_g1
    Rpl7 Ribosomal protein L7 Mm02342562_gH
    Rpl21 Ribosomal protein L21 Mm01216752_m1
    Rpl22 Ribosomal protein L22 Mm04410429_m1
    Rpl23a Ribosomal protein L23A Mm01614208_gH
    Rpl26 Ribosomal protein L26 Mm02343715_g1 
    Rpl27 Ribosomal protein L27 Mm01245874_g1
    Rpl30 Ribosomal protein L30 Mm01611464_g1
    Rps3A Ribosomal protein S3A Mm00656272_m1
    Rps5 Ribosomal protein S5 Mm00501433_m1
    Rps6 Ribosomal protein S6 Mm01263489_m1
    Rps10 Ribosomal protein S10 Mm02391992_g1 
    Rps13 Ribosomal protein S13 Mm01731324_g1
    Rps16 Ribosomal protein S16 Mm01617542_g1
    Rps17 Ribosomal protein S17 Mm01314921_g1 
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were calculated as the normalized CT values for 
each target gene in relation to the mean of 
endogenous controls GUS-β, XPNPEP1, AARS 
and HPRT in humans, whereas in mice hprt was 
the housekeeping gene selected for normaliza-
tion. Second, ΔΔCT values were obtained with 
the ΔCT of each sample minus the mean ΔCT of 
the population of control samples (calibrator 
samples). The fold-change was determined 
using the equation 2-ΔΔCT. 
Gel electrophoresis and western blotting from 
total homogenate
0.1 g of sample tissue (n = 28) from frontal cor-
tex area 8 in human cases and 0.1 g of somato-
sensory cortex in mice aged 3, 12 and 20 
months (n = 7 per age and phenotype) were 
lysed with a glass homogenizer in Mila lysis buf-
fer (0.5 M Tris at pH 7.4 containing 0.5 methyl-
enediaminetetraacetic acid at pH 8.0, 5 M 
NaCl, 0.5% Na doxicholic, 0.5% Nonidet P-40, 
1 mM phenylmethylsulfonyl fluoride, bi-distilled 
water, protease and phosphatase inhibitor 
cocktails (Roche Molecular Systems, Pleasan- 
ton, CA, USA), and then centrifuged for 15 min 
at 13,000 g in human cases and for 10 min at 
5,000 g in mice, at 4°C (Ultracentrifuge Be- 
ckman with 70Ti rotor, CA, USA). Protein con-
centration was measured with a Smarts- 
pectTMplus spectrophotometer (Bio-Rad, CA, 
USA) using the Bradford method (Merck, 
Darmstadt, Germany). Samples containing 
15μg of protein and the standard Precision 
Plus ProteinTM Dual Color (Bio-Rad) were loaded 
onto 10-15% w/v acrylamide gels. Proteins 
were separated in sodium dodecylsulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and 
electrophoretically transferred to nitrocellulose 
membranes using the Trans-Blot®TurboTM trans-
fer system (Bio-Rad) at 200 mA/membrane for 
40 min for human samples and at 50 mA/
membrane overnight for mouse samples. Non-
specific bindings were blocked by incubation in 
5 w/v% dry milk in Tris-buffered saline (TBS) 
containing 0.1% v/v Tween for 1 hour at room 
temperature. After washing, the membranes 
were incubated at 4°C overnight with one of 
the primary antibodies in TBS containing 3% 
w/v albumin and 0.1% v/v Tween. Primary anti-
bodies are detailed in Table 3. Monoclonal anti-
body anti-β-actin diluted 1:30,000 (β-actin, 
A5316; Sigma-Aldrich, St. Louis, MO, USA) was 
blotted for the control of protein loading in 
human samples and monoclonal anti-GAPDH 
(glyceraldehydes 3-phosphate dehydrogenase, 
ADI-CSA-335-E; Enzo Life Sciences, Inc., Far- 
mingdale, NY, USA) diluted 1:5,000 for mouse 
samples. Following incubation with one of the 
primary antibodies, membranes were incubat-
ed for 1 hour with the appropriate HRP-con- 
jugated secondary antibody (1:2,000, Dako, 
Glostrup, Denmark), and the immune complex-
es were revealed with a chemiluminescence 
reagent (ECL, Amersham, GE Healthcare, 
Buckinghamshire, UK). 
Statistical analysis
The normality of distribution of the mean fold-
change values obtained by RT-qPCR for every 
region and stage between controls and patho-
logical cases was analyzed with the Kolmogo- 
rov-Smirnov test. The non-parametric Mann-
Whitney test was performed to compare each 
group when the samples did not follow a nor-
mal distribution whereas the unpaired t test 
was used for normal variables. Statistical anal-
ysis was performed with GraphPad Prism ver-
sion 5.01 (La Jolla, CA, USA) and Statgraphics 
Statistical Analysis and Data Visualization 
Software version 5.1 (Warrenton, VA, USA). 
Differences between groups were considered 
Table 3. Primary antibodies used in the present study including reference, supplier, host and dilution
Antibody (anti-) Reference Supplier Host Dilution
β-actin A5316 Sigma-Aldrich, St Louis, MO, USA Ms 1/30000
eIF2α (eukaryotic initiation factor 2α) 5A5 Thermo Fisher Sci, Waltham, MA, USA Ms 1/50
eIF3η (eukaryotic initiation factor 3η) sc 2887 Santa Cruz, Dallas, TX, USA Rb 1/200
eIF5 (eukaryotic initiation factor 5) sc.282 Santa Cruz, Dallas, TX, USA Rb 1/400
eEF1A (eukaryotic elongation factor 1A) 2551 Cell Signaling, Danvers, MA, USA Rb 1/100
eEF2 (eukaryotic elongation factor 2) 2332 Cell Signaling, Danvers, MA, USA Ms 1/1,000
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) ADI-CSA-335-E Enzo Life Sciences, Incl., Farmingdale, NY, USA Ms 1/5000
P-eIF2α (phospho-eukaryotic initiation factor 2α pSer51) S.674.5 Thermo Fisher Sci, Waltham, MA, USA Rb 1/50
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statistically significant at p-values: *P<0.05, 
**P<0.01 and ***P<0.001.
Densitometry of western blot bands was 
assessed with the TotalLab program (TotalLab 
Quant, Newcastle, UK) and subsequently ana-
lyzed with GraphPad Prism and Statgraphics 
Statistical Analysis, and Data Visualization 
Software version 5.1 (VA, USA), with one-way 
ANOVA with post-hoc Tukey’s range test for mul-
tiple comparisons; differences were considered 
statistically significant with p-values: *P<0.05; 
**P<0.01; ***P<0.001. 
Results
Human cases: AD and rpAD
mRNA expression levels of nucleolar proteins, 
18S and 28S rRNA and ribosomal proteins in 
frontal cortex area 8 in MA, AD and rpAD: 
Genes encoding nucleolar proteins nucleo-
phosmin 1 (NPM1) and nucleolin (NCL), and 
upstream binding transcription factor (UBTF) 
were significantly down-regulated in AD (p val-
ues ranged from <0.05 to <0.01) and in rpAD (p 
values from <0.05 to <0.01) compared with 
MA. rRNA18S and rRNA28S expression levels 
were reduced in AD and rpAD (p values from 
<0.001 to <0.001). No significant differences 
were observed when comparing AD with rpAD 
(Table 4).
Three genes encoding ribosomal proteins 
RPL21, RPS6 and RPS10 were up-regulated, 
and two encoding RPL22 and RPS20 down-
regulated in AD when compared with MA (p val-
ues between <0.05 and <0.01). However, ten 
of seventeen genes encoding ribosomal pro-
teins were deregulated in rpAD when compared 
with MA. The expression of most of these 
genes, including RPL21, RPL23A, RPL31, 
RPS5, RPS6, RPS10, RPS13 and RPS17, was 
significantly increased, but RPL22 and RPS20 
were down-regulated (p values between <0.05 
Table 4. mRNA expression of genes coding for selected nucleolar and ribosomal proteins, rRNA18S 
and rRNA28S in frontal cortex area 8 in MA, AD and rpAD
MA AD rpAD MA vs AD MA vs rpAD AD vs rpAD
UBTF 1.069 ± 0.444 0.602 ± 0.124 0.574 ± 0.085 *,↓ **,↓ -
NPM1 1.078 ± 0.476 0.531 ± 0.077 0.593 ± 0.144 **,↓ *,↓ -
NCL 1.083 ± 0.472 0.646 ± 0.098 0.673 ± 0.123 *,↓ *,↓ -
rRNA18S 1.038 ± 0.270 0.702 ± 0.303 0.578 ± 0.126 *,↓ ***,↓ -
rRNA28S 1.113 ± 0.617 0.423 ± 0.230 0.385 ± 0.085 **,↓ *,↓ -
RPL5 1.008 ± 0.130 1.010 ± 0.165 1.039 ± 0.155 - - -
RPL7 1.007 ± 0.120 1.029 ± 0.183 1.091 ± 0.051 - - -
RPL21 1.085 ± 0.492 1.606 ± 0.559 1.606 ± 0.545 *,↑ *,↑ -
RPL22 1.013 ± 0.165 0.835 ± 0.139 0.855 ± 0.083 *,↓ *,↓ -
RPL23A 1.044 ± 0.318 1.140 ± 0.179 1.482 ± 0.363 - *,↑ *,↑
RPL26 1.020 ± 0.195 0.992 ± 0.295 0.947 ± 0.237 - - -
RPL27 1.009 ± 0.141 1.007 ± 0.129 0.746 ± 0.630 - - -
RPL30 1.032 ± 0.266 1.097 ± 0.547 0.921 ± 0.404 - - -
RPL31 1.010 ± 0.148 1.002 ± 0.115 1.170 ± 0.161 - *,↑ *,↑
RPS3A 1.031 ± 0.271 1.119 ± 0.423 0.919 ± 0.310 - - -
RPS5 1.006 ± 0.110 1.071 ± 0.209 1.261 ± 0.155 - ***,↑ -
RPS6 1.009 ± 0.134 1.255 ± 0.375 1.430 ± 0.373 *,↑ **,↑ -
RPS10 1.017 ± 0.191 1.223 ± 0.131 1.324 ± 0.242 *,↑ **,↑ -
RPS13 1.002 ± 0.072 1.031 ± 0.069 1.255 ± 0.217 - **,↑ *,↑
RPS16 1.019 ± 0.205 1.020 ± 0.243 0.845 ± 0.283 - - -
RPS17 1.004 ± 0.091 1.035 ± 0.133 1.252 ± 0.192 - **,↑ *,↑
RPS20 1.008 ± 0.140 0.819 ± 0.132 0.674 ± 0.234 **,↓ **,↓ -
The non-parametric Mann-Whitney test was performed to compare each group when the samples did not follow a normal 
distribution whereas the unpaired t test was used for normal variables. Data are represented as the mean ± SD: *P<0.05, 
**P<0.01 and ***P<0.001. ↓, ↑ indicate gene up-regulation and down-regulation, respectively.
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and <0.001). Four genes, including RPL23A, 
RPL31, RPS13 and RPS17, were differentially 
up-regulated in AD when compared with rpAD 
(P<0.05) (Table 4).
Expression levels of initiation and elongation 
factors of protein synthesis in frontal cortex 
area 8 in MA, AD and rpAD: Four eukaryotic ini-
tiation factors eIF2α, phospho-eIF2α, eIF3η 
and eIF5, and two eukaryotic elongation fac-
tors, eEF1A and eEF2, were assessed with 
western blotting.
eEF1A and eEF2 were significantly decreased 
in AD when compared with MA (P<0.01); eIF3η, 
eEF1A and eEF2 were significantly decreased 
in rpAD when compared with MA (p values from 
<0.01 to <0.001); eIF3η was significantly down-
Figure 1. Protein expression levels of eukaryotic initiation factors eIF2α, phospho-eIF2α, eIF3η and eIF5, and eu-
karyotic elongation factors, eEF1A and eEF2 as revealed with gel electrophoresis and western blotting in frontal 
cortex area 8 in MA, AD and rpAD, and corrected with β-actin. Densitometry of western blot bands was assessed 
with the TotalLab program and subsequently analyzed with GraphPad Prism and Statgraphics Statistical Analysis, 
and Data Visualization Software version 5.1 with one-way ANOVA with post-hoc Tukey’s range test for multiple com-
parisons: *P<0.05; **P<0.01; ***P<0.001.
Table 5. mRNA expression of genes coding for selected nucleolar and ribosomal proteins, rRNA18S 
and rRNA28S in the somatosensory cortex of WT and APP/PS1 mice aged 3, 12 and 20 months
3 months 12 months 20 months
WT APP/PS1 WT APP/PS1 WT APP/PS1
Ubtf 1.057 ± 0.111### 1.123 ± 0.211 1.628 ± 0.041 1.463 ± 0.083 1.342 ± 0.089 3.796 ± 0.873
Npm3 1.188 ± 0.305 1.023 ± 0.087& 0.862 ± 0.070 0.852 ± 0.082 2.518 ± 0.396 3.796 ± 0.873
Ncl 1.010 ± 0.059 1.023 ± 0.087 0.082 ± 0.070& 1.003 ± 0.238 0.960 ± 0.086 1.370 ± 0.080**,↑
rRNA18S 1.018 ± 0.075### 1.085 ± 0.164& 2.730 ± 0.188&&& 2.237 ± 0.456 1.259 ± 0.170 2.504 ± 0.496*,↑
rRNA28S 1.009 ± 0.052###,&&& 1.076 ± 0.150 2.367 ± 0.191 1.847 ± 0326 1.338 ± 0.175 2.401 ± 0.344*,↑
Rpl5 1.004 ± 0.032### 1.005 ± 0.038### 3.015 ± 0.327&&& 2.393 ± 0.122&&& 0.727 ± 0.047 1.190 ± 0.147
Rpl7 1.032 ± 0.093 1.029 ± 0.094 1.785 ± 0.279 1.305 ± 0.108 1.251 ± 0.211 1.366 ± 0.211
Rpl21 1.003 ± 0.031 1.018 ± 0.067 0.903 ± 0.113 0.635 ± 0.058 0.834 ± 0.116 0.956 ± 0.094
Rpl22 1.004 ± 0.037 1.010 ± 0.049 1.043 ± 0.180 0.758 ± 0.51 0.823 ± 0.073 1.011 ± 0.100
Rpl23a 1.009 ± 0.052 1.015 ± 0.049&&& 1.081 ± 0.085 0.794 ± 0.036&&& 1.005 ± 0.059 1.649 ± 0.108**,↑
Rpl26 1.024 ± 0.022 1.009 ± 0.49 1.459 ± 0.204 1.116 ± 0.108& 1.025 ± 0.172 1.679 ± 0.205
Rpl27 1.003 ± 0.28 1.004 ± 0.030 1.465 ± 0.158 1.255 ± 0.133 0.960 ± 0.434 1.129 ± 0.120
Rpl30 1.023 ± 0.098# 1.010 ± 0.049 0.729 ± 0.068 0.878 ± 0.205 0.838 ± 0.082 1.589 ± 0.263
Rps3a 1.001 ± 0.013## 1.000 ± 0.017 1.683 ± 0.199&& 1.384 ± 0.194 0.896 ± 0.036 1.336 ± 0.155*,↑
Rps5 1.002 ± 0.028## 1.006 ± 0.043#,& 1.987 ± 0.252& 1.698 ± 0.231 1.050 ± 0.053 1.576 ± 0.173*,↑
Rps6 1.003 ± 0.043 1.191 ± 0.245 1.184 ± 0.080 1.643 ± 0.127 1.006 ± 0.052 1.831 ± 0.255*,↑
Rps10 1.007 ± 0.045 1.013 ± 0.065### 3.730 ± 0.522&&& 3.344 ± 0.368 1.122 ± 0.083 1.884 ± 0.263*,↑
Rps13 1.001 ± 0.015### 1.004 ± 0.038# 0.803 ± 0.092&& 0.610 ± 0.021 0.778 ± 0.033 1.150 ± 0.128*,↑
Rps16 1.004 ± 0.032# 1.006 ± 0.042& 1.286 ± 0.106&& 1.268 ± 0.120 0.827 ± 0.057 1.433 ± 0.176*,↑
Rps17 1.004 ± 0.031 1.008 ± 0.049 1.202 ± 0.096 1.057 ± 0.084 0.901 ± 0.102 1.225 ± 0.154
The non-parametric Mann-Whitney test was performed to compare each group when the samples did not follow a normal distribution whereas the unpaired t test 
was used for normal variables. Data are represented as the mean values ± SD. *P<0.05, **P<0.01 compared with WT animals; &P<0.05, &&P<0.01, &&&P<0.001 
compared with 20 months; #P<0.05, ##P<0.01, ###P<0.001 compared with animals aged 12 months. Expression levels were calculated using Hprt for normalization. 
↑ indicate gene up-regulation.
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regulated in rpAD when compared with AD 
(P<0.05) (Figure 1).
mRNA expression levels of nucleolar proteins, 
rRNA18S and rRNA28S, and ribosomal pro-
teins in somatosensory cortex of APP/PS1 mice 
at 3, 12 and 20 months: Expression levels of 
rRNAs and several genes coding for ribosomal 
proteins varied with age in WT and APP/PS1 
mice, although no significant differences were 
seen between the two groups at the ages of 3 
months and 12 months. Values were higher at 
the age of 12 months when compared with the 
age of 3 months in both phenotypes. Values 
decreased after the age of 12 months in both 
groups. However, a significant increase in the 
expression of Ncl, rRNA18S, rRNA28S, Rpl23a, 
Rps3a, Rps5, Rps6, Rps10, Rps13 and Rps16 
mRNA was found in APP/PS1 transgenic mice 
when compared with WT littermates at the age 
of 20 months (p values from <0.05 to <0.01) 
(Table 5).
Protein expression of initiation and elongation 
transcription factors in somatosensory cortex 
in WT and APP/PS1 mice: eIF2α, eIF3η, eIF5, 
eEF1a and eEF2 protein levels were assessed 
with western blotting in WT and APP/PS1 at the 
ages of 3, 12 and 20 months. Western blots of 
all samples are shown in Figure 2. eIF2α was 
significantly increased in APP/PS1 animals at 
the age of 3 months when compared with age-
matched littermates; eIF5 was significantly 
decreased (P<0.01), as was eEF2 (P<0.01) in 
APP/PS1 transgenic mice when compared to 
WT at the age of 12 months (Figure 3).  
Discussion
Present observations show altered expression 
of genes and proteins involved in the protein 
synthesis machinery from the nucleolus to the 
ribosome in frontal cortex area 8 at advanced 
stages of AD and in the somatosensory cortex 
of APP/PS1 transgenic mice used as a model of 
AD-like β-amyloidopathy at advanced stages of 
the disease. 
However, alterations differ in humans and mice. 
NPM1, NCL and UBTF mRNA expression is 
reduced in AD whereas Ncl mRNA is up-regulat-
ed in transgenic mice. rRNA18S and rRNA28S 
are reduced in AD but significantly increased in 
transgenic mice. Several genes encoding ribo-
somal proteins of the large and small subunits 
are up- or down-regulated in AD, but seven out 
of fifteen assessed genes encoding ribosomal 
proteins are up-regulated in the APP/P1 mouse. 
This is accompanied by a significant decrease 
in the protein levels of elongating factors eEF1A 
and eEF2 in AD but only of eEF2 in mice when 
compared with age-matched controls. More- 
over, alterations are more marked in rpAD when 
compared with typical forms of AD, as several 
Figure 2. Western blots of the somatosensory cortex of WT and APP/PS1 transgenic mice at the ages of 3, 12 and 
20 months showing the expression of eIF2α, eIF3η, eIF5, eEF1a and eEF2 proteins.
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ribosomal protein mRNAs are up-regulated, 
and initiation factor eIF3η protein expression is 
reduced, in rpAD when compared with typical 
AD.
Changes in AD cannot be attributed to the mere 
loss of nerve cells, as some genes are up-regu-
lated in parallel to others which are down-regu-
lated. It may be argued that differences in gene 
expression are related to differences in cell 
type, but that all these factors are expressed in 
neurons and glial cells. 
Reduced expression of RNAs encoding nucleo-
lar chaperones and UBTF in frontal cortex par-
allels decreases mRNA and protein expression 
in the CA1 region of the hippocampus at 
advanced stages of AD [15]. Reduced rRNA 
expression in frontal cortex is in agreement 
with previous observations [2-4, 9] but only 
with expression levels in the CA1 region of hip-
pocampus at early and middle stages of the 
disease [15]. Increased expression of rRNA28S 
in CA1 at advanced stages of AD may be relat-
ed to the accompanying astrogliosis [15]. 
Regarding transcription of genes encoding ribo-
somal proteins, marked differences are seen 
between the hippocampus and frontal cortex, 
as the majority of assessed genes are down-
regulated in the CA1 region of the hippocampus 
and up-regulated in the frontal cortex at the 
same disease stage [15].
Finally, differences also exist in the expression 
of initiation and elongation factors between the 
hippocampus and frontal cortex at similarly 
advanced stages of the disease. eIF2 is mark-
edly increased in the hippocampus but not in 
the frontal cortex, whereas eEF1A and eEF2 
total levels do not differ in AD from those of 
age-matched controls in the hippocampus [15] 
but are markedly reduced in frontal cortex at 
the same stage of the disease. Regional differ-
ences in the neuronal responses may account 
for these differences in the populations of neu-
rons and glial cells between the hippocampus 
and the frontal cortex at the same stage of the 
disease. Moreover, discrete differences might 
not be identified using total brain homoge-
nates. As an example, no modifications in total 
levels of P-eIF2α were observed in the present 
study although P-eIF2α is expressed in only 
approximately 60% of neurofibrillary tangle 
(NFT)-containing neurons in the isocortex in 
Figure 3. Protein expression levels of eukaryotic initiation factors eIF2α, eIF3η and eIF5, and eukaryotic elonga-
tion factors, eEF1A and eEF2 as revealed with gel electrophoresis and western blotting in somatosensory cortex 
of WT and APP/PS1 transgenic mice at the ages of 3, 12 and 20 months. Densitometry of western blot bands was 
assessed with the TotalLab program and subsequently analyzed with GraphPad Prism and Statgraphics Statisti-
cal Analysis, and Data Visualization Software version 5.1 with one-way ANOVA with post-hoc Tukey’s range test for 
multiple comparisons: *P<0.05, **P<0.01 comparison with age-matched WT; §P<0.01, §§P<0.01, §§§P<0.001, 
comparison with mice aged 3 months; #P<0.05, ##P<0.01, comparison with mice aged 12 months. 
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AD, thus indicating that not all neurons with 
NFTs over-express phosphorylated P-eIF2α 
[12]. 
In summary, our observations, when compared 
with previous similar studies of ours focused on 
the hippocampus (), show marked regional dif-
ferences in the expression of players involved 
in the protein synthesis machinery at the same 
advanced stage of the disease. Alterations dif-
fer slightly between typical AD and those cases 
with rapid clinical course, while alterations dif-
fer between AD and APP/PS1 transgenic mice, 
implying there can be no direct application of 
the results in the mouse model to the human 
disease.  
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